Advertisement

Internal and Emergency Medicine

, Volume 3, Issue 2, pp 161–163 | Cite as

Acute tumor lysis syndrome after rituximab administration in Burkitt’s lymphoma

  • Zaher K. Otrock
  • Hassan A. Hatoum
  • Ziad M. SalemEmail author
CE - Letter to the Editor

Rituximab (Rituxan, Mabthera) is an anti-CD20 monoclonal antibody that mediates killing of CD20+ B-lymphocytes by a combination of complement-mediated lysis and antibody-dependent cytotoxicity [1]. It is considered a safe medication, and infusion-related side effects are generally manageable. These include fever, chills and rigors, and they occur in 50% of patients [2]. Rituximab has been considered a nontoxic alternative to chemotherapy regimens and has become part of standard therapy for patients with CD20-expressing B-cell lymphoma [3]. In patients with a large number of CD20+ cells, tumor lysis may occur. Acute tumor lysis syndrome (TLS) caused by rituximab has been reported in two patients with chronic lymphocytic leukemia [4, 5] and in three patients with non-Hodgkin’s lymphoma (NHL) [4, 6, 7]. We report another case of a patient with Burkitt’s lymphoma who experienced acute TLS upon treatment with rituximab.

A 53-year-old man presented to a hospital in Saudi Arabia in January...

Keywords

Uric Acid Chronic Lymphocytic Leukemia Bone Marrow Aspirate Tumor Lysis Syndrome Autoimmune Hemolytic Anemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Maloney DG, Smith B, Rose A (2002) Rituximab: mechanism of action and resistance. Semin Oncol 29 (1 Suppl 2):2–9PubMedCrossRefGoogle Scholar
  2. 2.
    Bienvenu J, Chvetzoff R, Salles G, et al (2001) Groupe d’Etude des Lymphomes de l’Adulte. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2:378–384PubMedCrossRefGoogle Scholar
  3. 3.
    Scott SD (1998) Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin’s lymphoma. Cancer Pract 6:195–197PubMedCrossRefGoogle Scholar
  4. 4.
    Yang H, Rosove MH, Figlin RA (1999) Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol 62:247–250PubMedCrossRefGoogle Scholar
  5. 5.
    Jensen M, Winkler U, Manzke O, Diehl V, Engert A (1998) Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 77:89–91PubMedCrossRefGoogle Scholar
  6. 6.
    Abou Mourad Y, Taher A, Shamseddine A (2003) Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20. Hematol J 4:222–224PubMedCrossRefGoogle Scholar
  7. 7.
    Jabr FI (2005) Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma. Int J Hematol 82:312–314PubMedCrossRefGoogle Scholar
  8. 8.
    Chasty RC, Liu-Yin JA (1993) Acute tumour lysis syndrome. Br J Hosp Med 49:488–492PubMedGoogle Scholar
  9. 9.
    Lerza R, Botta M, Barsotti B, et al (2002) Dexamethazone-induced acute tumor lysis syndrome in a T-cell malignant lymphoma. Leuk Lymphoma 43:1129–1132PubMedCrossRefGoogle Scholar
  10. 10.
    Coutinho AK, de O Santos M, Pinczowski H, Feher O, del Giglio A (1997) Tumor lysis syndrome in a case of chronic lymphocytic leukemia induced by high-dose corticosteroids. Am J Hematol 54:85–86PubMedCrossRefGoogle Scholar
  11. 11.
    Malik IA, Abubakar S, Alam F, Khan A (1994) Dexamethasone-induced tumor lysis syndrome in high-grade non-Hodgkin’s lymphoma. South Med J 87:409–411PubMedGoogle Scholar
  12. 12.
    Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116:546–554PubMedCrossRefGoogle Scholar
  13. 13.
    Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11PubMedCrossRefGoogle Scholar
  14. 14.
    Jasek AM, Day HJ (1994) Acute spontaneous tumor lysis syndrome. Am J Hematol 47:129–131PubMedCrossRefGoogle Scholar
  15. 15.
    Lin TS, Lucas MS, Byrd JC (2003) Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 30:483–492PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2008

Authors and Affiliations

  • Zaher K. Otrock
    • 1
  • Hassan A. Hatoum
    • 1
  • Ziad M. Salem
    • 1
    Email author
  1. 1.Division of Hematology/Oncology, Department of Internal MedicineAmerican University of Beirut Medical CenterBeirutLebanon

Personalised recommendations